Faculty profile
Alexander Wyatt
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper.
Current oncology (Toronto, Ont.) · 2026
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer.
Cancers · 2021
Latest funding
- $6,000
Multiomic biomarker development for first-line therapy response in metastatic urothelial carcimona
CIHR · 2025 · Supervisor
- $1,005,976
Defining circulating tumor DNA kinetics as a treatment response biomarker in metastatic prostate cancer
CIHR · 2025 · Nominated PI
- $2,487,015
TRIPLE-SWITCH: A Randomized Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors (ARPI) and Androgen Deprivation Treatment (ADT) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response.
CIHR · 2024 · Co-investigator
3 publications.
Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper.
Schaeffer DF, Chan J, Morin J, Guiot MC, Yousef GM, Streutker CJ, Sekhon H, Fitzpatrick M, Virk S, Wyatt A, Spatz A, Shepherd L, Loree JM, Kinloch M, CCTG Pathology Working Group
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT
Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer.
De Laere B, Crippa A, Mortezavi A, Ghysel C, Rajan P, Eklund M, Wyatt A, Dirix L, Ost P, Grönberg H, Lindberg J, On Behalf Of The Core And ProBio Investigators
Multiomic biomarker development for first-line therapy response in metastatic urothelial carcimona
Principal investigators: Stephenson, Maria R
Keywords: Urothelial Carcimona; Biomarker Development
Defining circulating tumor DNA kinetics as a treatment response biomarker in metastatic prostate cancer
Principal investigators: Wyatt, Alexander W; Chi, Kim N
Keywords: Biomarker; Cancer Genomics; Ctdna; Liquid Biopsy; Prostate Cancer; Treatment Resistance
TRIPLE-SWITCH: A Randomized Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors (ARPI) and Androgen Deprivation Treatment (ADT) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response.
Principal investigators: Ong, Michael; Jafri, mariam
Keywords: Androgen Deprivation Treatment (Adt); Androgen Receptor Pathway Inhibitors (Arpi); Circulating Tumour Dna (Ctdna); Docetaxel; International; Metastatic Castration-Sensitive Prostate Cancer; Prostate Specific Antigen (Psa); Randomized Controlled Trial
Multiomic biomarker development for first-line therapy response in metastatic urothelial carcinoma
Principal investigators: Stephenson, Maria R
Keywords: Biomarker Development; Circulating Tumor Dna (Ctdna); Epigenomics; Genomics; Multiomics; Precision Oncology; Transcriptomics; Urothelial Cancer
oPTion-DDR: A randomized phase III trial investigating Platinum and Taxane chemotherapy in metastatic castration resistant prostate cancer patients with alterations in DNA Damage Response (DDR) genes
Principal investigators: Kolinsky, Michael; Jafri, mariam
Keywords: Dna Damage Response (Ddr) Genes; Economics; Genomic Testing; Metastatic Castration-Resistant Prostate Cancer; Patient-Reported Outcomes; Personalized Medicine; Platinum Chemotherapy; Quality Of Life; Randomized Controlled Trial
Refining the clinical utility of circulating tumour DNA in metastatic bladder cancer
Principal investigators: Wyatt, Alexander W; Eigl, Bernhard J
Keywords: Bladder Cancer; Cancer Genomics; Circulating Tumour Dna (Ctdna); Clinical Outcomes; Metastatic Progression; Treatment Resistance
Genomic dissection of de novo metastatic prostate cancer prior to treatment
Principal investigators: Wyatt, Alexander W; Chi, Kim N; Ost, Piet
Keywords: Cancer Genomics; Circulating Tumour Dna (Ctdna); Metastatic Progression; Prostate Cancer
Determining biomarkers of response to docetaxel chemotherapy in men with metastatic castration resistant prostate cancer.
Principal investigators: Herberts, Cameron
Keywords: Bioinformatics; Chemotherapy; Circulating Tumour Dna; Dna Biomarkers; Next Generation Sequencing; Prostate Cancer Genomics
Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations
Principal investigators: Warner, Evan
Keywords: Circulating Tumour Dna; Dna Damage Repair; Genomics; Liquid Biopsy; Precision Oncology; Prostate Cancer
Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer using circulating cell-free tumour DNA
Principal investigators: Herberts, Cameron
Keywords: Cancer Genomics; Chemotherapy; Circulating-Tumour Dna; Genomic Biomarkers; Next-Generation Sequencing; Precision Oncology; Prostate Cancer
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Jennifer Chan and Alexander Wyatt: 1 shared paper
- Alexander Wyatt and Alejandro Berlin: 1 shared paper
- Urologic Sciences
- Radiation Oncology/Medical Physics
- Pathology and Laboratory Medicine
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.